Dermatology News

Although rates of skin cancer in young people in England have stabilised during the last two decades, the incidence in older populations has increased substantially, according to new research.

People with relapsed multiple myeloma who have had one previous therapy will be able to access another innovative treatment option, daratumumab, through the Cancer Drugs Fund.

People showing erythema migrans, the characteristic skin rash associated with Lyme disease, can be diagnosed without the need for blood tests, NICE says in new guidance.

The National Osteoporosis Society has launched updated practical clinical guidelines on vitamin D to provide clarity for healthcare professionals at its national biennial conference, Osteoporosis 2018.

Patients with a type of advanced skin cancer have a new treatment option as pembrolizumab, also known as Keytruda, has been recommended for use on the Cancer Drugs Fund.

Hundreds of patients with a type of advanced skin cancer are set to benefit from a new treatment, dabrafenib plus trametinib.

Multiple myeloma: patients' appeal denied.   

Plitidepsin (Aplidin®), a new medicine for the treatment of relapsed and refractory myeloma, has received a second negative recommendation from the Committee for Medicinal Products for Human Use (CHMP). This decision means that plitidepsin is very unlikely to be made available to patients across Europe.